CTIS2022-501760-17-00招募中1 期
ongitudinal study of clinical outcome measures in adult patients with Spinal Muscular Atrophy (SMA) treated with Risdiplam. - version 4.0
Z Leuven0 个研究点目标入组 20 人开始时间: 2022年9月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Participants eligible for inclusion in this Trial must meet all of the following criteria: 1)Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures; 2) Use of highly effective methods of birth control; Highly effective contraceptives are methods that can achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include: • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal); • progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); • intrauterine device (IUD); • intrauterine hormone-releasing system ( IUS); • bilateral tubal occlusion; • vasectomised partner; • sexual abstinence. A male participant who is sexually active with a woman of childbearing potential and who has not had a vasectomy must agree to use a barrier method of birth control (eg, either a condom [with spermicidal foam/gel/film/cream/suppository or a partner with an occlusive cap [diaphragm or cervical/vault caps] plus spermicidal foam/gel/film/cream/suppository), during the study and for at least 4 months after receiving the last administration of Risdiplam. The time period during which highly effective contraception is required after the last dose of Risdiplam is 1 month for female patients of childbearing potential and 4 months for male patients. Male participants will be informed that they may consider sperm preservation prior to treatment initiation; 3)Male or female patients of an adult age (i.e., 18 years or older); 4)Confirmed genetic diagnosis of 5q-autosomal recessive Spinal Muscular Atrophy (SMA) (i.e., deletions of both SMN1-genes or mutations in both SMN1- genes have been genetically proven); 5)Patients eligible for treatment with Risdiplam (Evrysdi®) (i.e., SMA type 2 or 3 or patients with up to 4 SMN2-gene copies and no permanent invasive ventilation, corresponding to the RIZIV reimbursement criteria for Evrysdi® (Risdiplam) in Belgium) ), that are either treatment-naive or are already being treated with Evrysdi® (Risdiplam) in Standard-Of-Care.
排除标准
- •Participants eligible for this Trial must not meet any of the following criteria: 1)Any disorder, which in the Investigator’s opinion might jeopardise the participant’s safety or compliance with the protocol; 2) Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate, highly effective contraceptive. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. Exclusion criterion is a male participant who is sexually active with a woman of childbearing potential and who has not had a vasectomy and does not agree to use a barrier method of birth control (e.g. a condom) during the study until at least 4 months after the last dose of Risdiplam; 3)Participation in an interventional Trial with an investigational medicinal product (IMP) or device; 4) Patients younger than 18 years of age at the time of the study; 5) Patients without genetically confirmed diagnosis of 5q-SMA at the time of the study; 6) SMA patients not eligible for treatment with Risdiplam according to the RIZIV reimbursement criteria for Risdiplam (Evrysdi®) in Belgium; 7) Patients treated with Risdiplam (Evrysdi®) in a Compassionate Use Programme (CUP) at the time of inclusion; 8) Patients treated with nusinersen (Spinraza®) before or at the time of inclusion.
研究者
相似试验
已完成
4 期
An obsevational study to compare the effects of anti allergic eyedrops in patients of allergic conjunctivitis.CTRI/2018/03/012788All India Institute of Medical SciencesRishikesh60
已完成
不适用
Prospective assessment of the clinical outcome of patients with primary breast cancer who have been tested with the EndoPredict gene expression test - a prospective care research study (RESCUE, Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer)C50Malignant neoplasm of breastDRKS00014051OGGO e.V.1,191
招募中
不适用
Observational study for clinical outcome and quality of life in patients after each treatment for prostate cancer.Prostate cancerJPRN-UMIN000035120ara Medical University1,250
进行中（未招募）
3 期
Study to evaluate the effect of fluticasone furoate/vilanterol on survivalin subjects with chronic obstructive pulmonary disease who have history of cardiovascular disease.CTRI/2012/04/002563GlaxoSmithKline16,000
进行中（未招募）
不适用
Study to evaluate the effect of fluticasone furoate/vilanterol on survival in subjects with chronic obstructive pulmonary disease.EUCTR2010-021638-72-ITGLAXO SMITH KLINE RESEARCH & DEVELOPMENT LTD16,000